Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine plus docetaxel for KRAS G12D-mutant advanced NSCLC (single-arm phase 2)
ChiCTR2600125260Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and glutamine in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective response rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
docetaxelglutamine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600125260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125260.